» Articles » PMID: 32898724

MicroRNAs As Mediators of Drug Resistance Mechanisms

Overview
Specialty Pharmacology
Date 2020 Sep 8
PMID 32898724
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs are small RNA transcripts involved in fine-tuning of several cellular mechanisms and pathways crucial for maintaining cells' homeostasis like apoptosis, differentiation, inflammation and cell-cycle regulation. They act by regulation of gene expression at post-transcriptional level through fine-tuning of target proteins expression. Expression of microRNAs is cell-type specific and since their discovery they have been proven to be deregulated in various disorders including cancer. Several lines of evidence are emerging that link microRNAs to drug resistance mechanisms in tumours given their important role in modulating oncogenic and tumour suppressive mechanisms. This review will focus on latest knowledge of the roles and mechanisms of microRNAs as mediators to drug resistance and the implications for future therapies.

Citing Articles

Mitochondria-associated non-coding RNAs and their impact on drug resistance.

An X, Sun L, Zheng H, Xiao Y, Sun W, Yu D Front Pharmacol. 2025; 16:1472804.

PMID: 40078288 PMC: 11897306. DOI: 10.3389/fphar.2025.1472804.


Effective Strategies in Designing Chitosan-hyaluronic Acid Nanocarriers: From Synthesis to Drug Delivery Towards Chemotherapy.

Hong L, Ho T, Cu S, Ngan L, Quyen Tran N, Dang T Curr Drug Deliv. 2024; 22(1):41-62.

PMID: 38310441 DOI: 10.2174/0115672018275983231207101222.


Recent advances on high-efficiency of microRNAs in different types of lung cancer: a comprehensive review.

Sadeghi M, Lotfi M, Soltani N, Farmani E, Fernandez J, Akhlaghitehrani S Cancer Cell Int. 2023; 23(1):284.

PMID: 37986065 PMC: 10661689. DOI: 10.1186/s12935-023-03133-z.


Prospects of microRNAs as therapeutic biomarkers in non-small cell lung cancer.

Samson J, Parvathi V Med Oncol. 2023; 40(12):345.

PMID: 37922117 DOI: 10.1007/s12032-023-02212-5.


MiR-145 inhibits cell migration and increases paclitaxel chemosensitivity in prostate cancer cells.

Tohidast M, Memari N, Amini M, Hosseini S, Jebelli A, Doustvandi M Iran J Basic Med Sci. 2023; 26(11):1350-1359.

PMID: 37886001 PMC: 10598815. DOI: 10.22038/IJBMS.2023.70878.15397.